1. Home
  2. IGC vs KNW Comparison

IGC vs KNW Comparison

Compare IGC & KNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • KNW
  • Stock Information
  • Founded
  • IGC 2005
  • KNW 1998
  • Country
  • IGC United States
  • KNW United States
  • Employees
  • IGC N/A
  • KNW N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • KNW Industrial Machinery/Components
  • Sector
  • IGC Health Care
  • KNW Industrials
  • Exchange
  • IGC Nasdaq
  • KNW Nasdaq
  • Market Cap
  • IGC 29.4M
  • KNW 23.8M
  • IPO Year
  • IGC N/A
  • KNW N/A
  • Fundamental
  • Price
  • IGC $0.37
  • KNW $0.16
  • Analyst Decision
  • IGC Strong Buy
  • KNW Buy
  • Analyst Count
  • IGC 2
  • KNW 1
  • Target Price
  • IGC $3.75
  • KNW $1.00
  • AVG Volume (30 Days)
  • IGC 469.7K
  • KNW 1.0M
  • Earning Date
  • IGC 02-12-2025
  • KNW 02-12-2025
  • Dividend Yield
  • IGC N/A
  • KNW N/A
  • EPS Growth
  • IGC N/A
  • KNW N/A
  • EPS
  • IGC N/A
  • KNW N/A
  • Revenue
  • IGC $1,183,000.00
  • KNW N/A
  • Revenue This Year
  • IGC N/A
  • KNW N/A
  • Revenue Next Year
  • IGC $13.57
  • KNW N/A
  • P/E Ratio
  • IGC N/A
  • KNW N/A
  • Revenue Growth
  • IGC N/A
  • KNW N/A
  • 52 Week Low
  • IGC $0.27
  • KNW $0.13
  • 52 Week High
  • IGC $0.91
  • KNW $0.92
  • Technical
  • Relative Strength Index (RSI)
  • IGC 49.16
  • KNW 38.30
  • Support Level
  • IGC $0.33
  • KNW $0.17
  • Resistance Level
  • IGC $0.38
  • KNW $0.37
  • Average True Range (ATR)
  • IGC 0.03
  • KNW 0.04
  • MACD
  • IGC -0.00
  • KNW -0.00
  • Stochastic Oscillator
  • IGC 44.44
  • KNW 14.54

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About KNW Know Labs Inc.

Know Labs Inc is a medical diagnostic. The company is focused on the development, marketing, and sales of proprietary technologies that are capable of uniquely identifying or authenticating almost any substance or material using electromagnetic energy to record, detect, and identify the signature of the substance or material known as Bio-RFID and ChromaID technologies. It is developing a wearable device that will measure blood glucose without fingersticks or microneedles.

Share on Social Networks: